Press release
Artificial Intelligence (AI) in Pharmaceutical Market to Reach USD 28.63 Billion by 2034, Growing at a CAGR of 31.2%
Artificial Intelligence (AI) in Pharmaceutical Market
Market Overview
The market has witnessed rapid momentum, propelled by rising adoption of machine learning, natural language processing, and generative AI tools across drug discovery, clinical trial design, and pharmacovigilance workflows. Pharmaceutical companies are increasingly deploying predictive analytics and deep learning models to shorten R&D timelines and lower the historically high cost of bringing a new therapy to market. Expanding collaboration between pharma majors and AI technology providers, along with growing cloud-based deployment, is accelerating adoption, and demand is expected to stay resilient as regulators grow more receptive to AI-assisted development.
πExplore the Research Before You Buy β Request a Sample:
https://www.polarismarketresearch.com/industry-analysis/artificial-intelligence-ai-in-pharmaceutical-market
Key Market Insights
β’ Natural language processing led the technology landscape with a 35.64% revenue share in 2025, as it simplifies translation of complex biological and clinical data into narrative insights for researchers.
β’ North America accounted for the largest revenue share in 2025 at 49.80%, while Asia Pacific is projected to post the fastest growth on the back of expanding biotechnology research and healthcare investment.
β’ Cloud-based deployment led the market in 2025, as pay-per-use AI services help pharmaceutical firms avoid the heavy upfront hardware and IT staffing costs tied to on-premises infrastructure.
β’ Generative AI adoption is rising quickly across drug discovery, with platforms used to design novel molecular structures, predict protein interactions, and shorten candidate-screening cycles.
β’ Strategic collaborations between pharmaceutical companies and AI technology vendors continue to shape competitive activity and accelerate pipeline development.
Market Dynamics
β’ Driver: Growing complexity of modern pharmacology is pushing companies toward AI-assisted research and development.
β’ Driver: Persistently high clinical trial failure rates and costs are prompting broader use of AI-driven candidate screening.
β’ Opportunity: Use of AI to mine electronic health records for faster patient recruitment and real-time adaptive trial design presents a growth avenue.
β’ Restraint: High implementation costs and technological complexity remain a barrier for smaller organizations.
β’ Restraint: Limited acceptability among some providers and a shortage of experienced AI talent may slow adoption.
β’ Opportunity: Rising government support for AI-powered pharmaceutical technology across China, India, and South Korea is opening expansion avenues.
β’ Opportunity: Deepening collaboration between AI startups and established pharmaceutical companies is creating platform-level partnership opportunities.
Market Segmentation
The market is segmented based on technology, offering, deployment, application, end use, and region. By technology, it spans machine learning, natural language processing, deep learning, and other AI techniques supporting pharmaceutical research. By offering, it includes hardware, software, and services, while deployment is categorized into cloud and on-premises models. By application, demand covers drug discovery, precision medicine, medical imaging and diagnostics, and broader research use cases, with end users spanning pharma and biotech companies, hospitals, and academic and research institutes. Regionally, the market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
πGet the Insights You Need to Plan Your Next Business Move:
https://www.polarismarketresearch.com/industry-analysis/artificial-intelligence-ai-in-pharmaceutical-market/pricing
Regional Insights
β’ North America: Held the leading position with a 49.80% revenue share in 2025, underpinned by a strong base of pharmaceutical majors and mature healthcare infrastructure.
β’ Asia Pacific: Expected to register the fastest growth through the forecast period, driven by expanding biotechnology research and government initiatives in China, India, and South Korea.
β’ Europe: Maintains a steady growth position, supported by established R&D hubs and rising cloud-based analytics adoption.
β’ Latin America & Middle East and Africa: Represent emerging markets, with gradual uptake supported by expanding healthcare digitization initiatives.
Competitive Landscape
The market is moderately consolidated, with key players focusing on platform innovation, strategic collaborations, and computational drug discovery capabilities to strengthen their market position. Many AI-focused biotechnology startups are partnering directly with pharmaceutical companies to accelerate development of advanced therapeutics, while leading technology providers continue to expand cloud-based pharmaceutical analytics offerings. Mergers, acquisitions, and cross-industry collaborations remain common strategies for broadening geographic presence and deepening R&D pipelines.
Some of the key players operating in the market include AstraZeneca LLC, Atomwise Inc., Bayer AG, Cloud Pharmaceuticals Inc, GNS Healthcare, IBM Watson, Merck & Co., Microsoft Corporation, Novartis AG, NVIDIA Corporation, Pfizer Inc., Recursion Pharmaceuticals Inc., and XtalPi Inc., among others.
Recent Developments
β’ January 2026: AstraZeneca announced the acquisition of Modella AI, an AI company for life sciences, extending an existing collaboration to expand AI data models and analytical tools within AstraZeneca's global oncology pipeline.
β’ January 2026: NVIDIA and Eli Lilly announced a co-innovation AI lab, with plans to jointly invest up to USD 1 billion over five years in infrastructure and research to accelerate drug discovery.
β’ April 2026: Novo Nordisk announced a strategic partnership with OpenAI to integrate AI capabilities globally, spanning drug discovery through manufacturing and commercial operations.
β’ July 2026: Insilico Medicine announced a strategic collaboration with Takeda to apply its Pharma.AI platform toward identifying clinically differentiated drug candidates.
More Trending Latest Reports By Polaris Market Research:
Cell Culture Matrices Market:
https://www.polarismarketresearch.com/industry-analysis/cell-culture-matrices-market
Prehabilitation Market:
https://www.polarismarketresearch.com/industry-analysis/prehabilitation-market
Value-based Healthcare Services Market:
https://www.polarismarketresearch.com/industry-analysis/value-based-healthcare-services-market
Exosomes Market:
https://www.polarismarketresearch.com/industry-analysis/exosomes-market
Contact Us
Polaris Market Research & Consulting, Inc.
8 The Green Ste 19824, Dover, DE 19901, United States
Phone: +1 929-297-9727
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
About Polaris Market Research & Consulting, Inc.
Polaris Market Research is a global market intelligence and consulting company dedicated to delivering in-depth business insights and actionable research. We specialize in providing syndicated reports, customized consulting solutions, and strategic advisory services across diverse industries -- including healthcare, chemicals, energy, automotive, technology, and consumer goods. Our research methodology combines quantitative data with qualitative expertise, ensuring our clients receive accurate market sizing, growth forecasts, competitive analysis, and emerging trend insights. Polaris Market Research is a trusted partner to leading corporations, consulting firms, and government organizations worldwide, helping businesses make informed strategic decisions and identify new growth opportunities in rapidly evolving markets. Learn more at www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Artificial Intelligence (AI) in Pharmaceutical Market to Reach USD 28.63 Billion by 2034, Growing at a CAGR of 31.2% here
News-ID: 4627920 • Views: β¦
More Releases from Polaris Market Research & Consulting
Flexible Electronics Market to Reach USD 79.49 Billion by 2034, Growing at a CAG β¦
According to a new report published by Polaris Market Research, the global flexible electronics market was valued at USD 32.68 billion in 2025 and is projected to reach USD 79.49 billion by 2034, expanding at a CAGR of 10.4% during the forecast period.
Market Overview
The market has witnessed steady momentum in recent years, driven by rising demand for foldable displays, wearable technology, and lightweight consumer devices across healthcare, automotive, andβ¦
Recycled Carbon Fiber Market to Reach USD 440.58 Million by 2034, Growing at a C β¦
According to a new report published by Polaris Market Research, the global recycled carbon fiber market was valued at USD 201.19 million in 2025 and is projected to reach USD 440.58 million by 2034, expanding at a CAGR of 9.1% during the forecast period.
Market Overview
The market has witnessed steady growth in recent years, driven by rising demand for lightweight composite materials across the automotive, aerospace, and wind energy industries,β¦
Farm Management Software Market to Reach USD 9.69 Billion by 2034, Growing at a β¦
According to a new report published by Polaris Market Research, the global Farm Management Software market was valued at USD 3.79 billion in 2025 and is projected to reach USD 9.69 billion by 2034, expanding at a CAGR of 11.0% during the 2026-2034 forecast period.
Market Overview
The market has witnessed steady growth in recent years, driven by rising global food demand, expanding adoption of precision agriculture software, and continuous advancementsβ¦
Bone Growth Stimulator Market to Reach USD 1,855.88 Million by 2034, Growing at β¦
According to a new report published by Polaris Market Research, the global bone growth stimulator market was valued at USD 1,186.12 million in 2025 and is projected to reach USD 1,855.88 million by 2034, expanding at a CAGR of 5.1% during the forecast period.
Market Overview
The market has witnessed steady growth in recent years, driven by the rising incidence of bone fractures, growing prevalence of osteoporosis, and continuous advancements in biophysicalβ¦
More Releases for Pharma
Schizophrenia Market Gains Momentum with Expanding Pipeline and Investment Poten β¦
The Key Schizophrenia Companies in the market include - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Acadia Pharmaceuticals, Boehringer Ingelheim, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailedβ¦
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva β¦
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand theβ¦
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi β¦
πππ, πππ° πππ«π¬ππ²- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasingβ¦
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi β¦
πππ, πππ° πππ«π¬ππ²- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. Asβ¦
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh β¦
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of theβ¦
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, β¦
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoringβ¦
